DoMore Diagnostics was established to meet the need for novel methods in precision medicine to personalize treatment for cancer patients. It is based on prominent research from leading institutions such as Oslo University Hospital, Oxford University, and University College of London.

The company specializes in developing diagnostic methods for cancer based on artificial intelligence (AI). Their technology aims to utilize AI in digital pathology to reduce over- and undertreatment in cancer, addressing the global challenge of lacking objective and precise methods for cancer prognosis.

DoMore Diagnostics' mission is to bring AI-powered digital biomarkers closer to clinicians and patients, enabling personalized cancer treatment to improve patient outcomes and lower healthcare costs.

Torbjørn Furuseth, MD - Chief Executive Officer (CEO) & Co-founder

Sepp De Raedt, PhD - Chief Technology Officer (CTO) & Co-founder

Elisabeth M.J. Klaussen, MSc - Head of Quality and Regulatory

Andreas Berg Storsve, PhD - VP Operations

Lao Saal, MD, PhD - Medical Director

https://www.linkedin.com/company/domore-diagnostics/

Currently, there are no open positions listed on their site. Interested candidates are encouraged to contact the company directly.